3/27
08:15 am
xfor
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.
Medium
Report
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.
3/26
10:27 am
xfor
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $3.00 price target on the stock.
Low
Report
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $3.00 price target on the stock.
3/25
06:10 am
xfor
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/25
06:01 am
xfor
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
High
Report
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
3/11
08:00 am
xfor
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
Low
Report
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
2/19
07:55 am
xfor
X4 Pharmaceuticals partners with taiba rare for distribution of XOLREMDI drug [Seeking Alpha]
Low
Report
X4 Pharmaceuticals partners with taiba rare for distribution of XOLREMDI drug [Seeking Alpha]
2/19
07:35 am
xfor
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
Low
Report
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
2/7
08:28 am
xfor
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.
Low
Report
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.
2/6
08:11 am
xfor
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia [Yahoo! Finance]
Medium
Report
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia [Yahoo! Finance]
2/6
07:35 am
xfor
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
Medium
Report
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
2/3
04:05 pm
xfor
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/24
07:36 am
xfor
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
Medium
Report
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
1/14
08:02 am
xfor
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.
High
Report
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.
1/13
07:35 am
xfor
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
Medium
Report
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand